AR065362A1 - Utilizacion de lactobacillus casei para reforzar la proteccion inducida por la vacunacion antigripal - Google Patents

Utilizacion de lactobacillus casei para reforzar la proteccion inducida por la vacunacion antigripal

Info

Publication number
AR065362A1
AR065362A1 ARP080100645A ARP080100645A AR065362A1 AR 065362 A1 AR065362 A1 AR 065362A1 AR P080100645 A ARP080100645 A AR P080100645A AR P080100645 A ARP080100645 A AR P080100645A AR 065362 A1 AR065362 A1 AR 065362A1
Authority
AR
Argentina
Prior art keywords
vaccination
lactobacillus casei
antigripal
strengthen
protection induced
Prior art date
Application number
ARP080100645A
Other languages
English (en)
Inventor
Sandrine Samson-Villeger
Raphaelle Bourdet-Sicard
Original Assignee
Gervais Danone Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gervais Danone Sa filed Critical Gervais Danone Sa
Publication of AR065362A1 publication Critical patent/AR065362A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Utilizacion de lactobacillus casei en composiciones a las que se puede administrar por via oral, para intensificar la proteccion que, contra la gripe, viene a continuacion de la vacunacion antigripal, al potenciar la respuesta humoral que esavacunacion induce.
ARP080100645A 2007-02-16 2008-02-15 Utilizacion de lactobacillus casei para reforzar la proteccion inducida por la vacunacion antigripal AR065362A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0701140A FR2912657B1 (fr) 2007-02-16 2007-02-16 Utilisation de lactobacillus casei pour renforcer la protection induite par la vaccination anti-grippale.

Publications (1)

Publication Number Publication Date
AR065362A1 true AR065362A1 (es) 2009-06-03

Family

ID=38508753

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100645A AR065362A1 (es) 2007-02-16 2008-02-15 Utilizacion de lactobacillus casei para reforzar la proteccion inducida por la vacunacion antigripal

Country Status (16)

Country Link
US (1) US8349315B2 (es)
EP (1) EP2120590B1 (es)
JP (1) JP2010518151A (es)
KR (1) KR20090115960A (es)
CN (1) CN101918013A (es)
AR (1) AR065362A1 (es)
AT (1) ATE530070T1 (es)
BR (1) BRPI0807649A2 (es)
CA (1) CA2678004A1 (es)
ES (1) ES2378052T3 (es)
FR (1) FR2912657B1 (es)
MX (1) MX2009008767A (es)
PL (1) PL2120590T3 (es)
RU (1) RU2470994C2 (es)
WO (1) WO2008129148A2 (es)
ZA (1) ZA200905551B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2937252B1 (fr) 2008-10-17 2011-05-20 Pf Medicament Association d'un extrait de sureau et d'une souche de l. paracasei.
KR101806435B1 (ko) * 2010-10-15 2017-12-07 시에이치알. 한센 에이/에스 면역보강제
WO2014038929A1 (en) 2012-09-07 2014-03-13 N.V. Nutricia Probiotics for producing antiviral factors
EP3040083B1 (en) * 2013-08-26 2018-11-21 Meiji Co., Ltd. Antibody titer-increasing agent using lactic acid bacterium
WO2018220416A1 (en) * 2017-05-31 2018-12-06 Compagnie Gervais Danone Lactobacillus paracasei strain capable of improving the immune response to a viral-bacterial coinfection
US20240408154A1 (en) * 2021-11-02 2024-12-12 Kabushiki Kaisha Yakult Honsha Enhancer of number of tcr clones

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1289984B1 (it) * 1997-02-27 1998-10-19 Proge Farm Srl Ceppi di lattobacilli utili nel trattamento di disfunzioni del sistema gastrointestinale
FR2809312B1 (fr) * 2000-05-25 2002-07-12 Gervais Danone Sa Utilisation de l. casei dans des compositions immunostimulantes
WO2006124630A2 (en) * 2005-05-13 2006-11-23 New England Medical Center Hospitals, Inc. Compositions and methods for enhancing the efficacy of vaccines

Also Published As

Publication number Publication date
WO2008129148A3 (fr) 2009-02-12
US8349315B2 (en) 2013-01-08
RU2470994C2 (ru) 2012-12-27
PL2120590T3 (pl) 2012-05-31
MX2009008767A (es) 2009-10-12
CA2678004A1 (fr) 2008-10-30
FR2912657A1 (fr) 2008-08-22
FR2912657B1 (fr) 2009-04-17
CN101918013A (zh) 2010-12-15
KR20090115960A (ko) 2009-11-10
WO2008129148A2 (fr) 2008-10-30
EP2120590B1 (fr) 2011-10-26
US20100129334A1 (en) 2010-05-27
JP2010518151A (ja) 2010-05-27
ATE530070T1 (de) 2011-11-15
RU2009134520A (ru) 2011-03-27
ES2378052T3 (es) 2012-04-04
ZA200905551B (en) 2010-05-26
BRPI0807649A2 (pt) 2014-06-10
EP2120590A2 (fr) 2009-11-25

Similar Documents

Publication Publication Date Title
EP1984405A4 (en) INFLUENZA ANTIGENES, VACCINE COMPOSITIONS AND RELATED METHODS
IL186611A0 (en) Vaccine against pandemic strains of influenza viruses
CO6331297A2 (es) Composiciones adyuvantes novedosas
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
BR112014014341A2 (pt) Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
GEP20207129B (en) Inhibitors of influenza viruses replication
UY31526A1 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
MX2013011336A (es) Composiciones farmaceuticas intranasales de benzodiazepina.
BR112014014315A2 (pt) composições aquosas de higiene oral
MY155564A (en) Arginine salts and their uses for the treatment of illnesses in the oral cavity
ECSP12012208A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
AR065362A1 (es) Utilizacion de lactobacillus casei para reforzar la proteccion inducida por la vacunacion antigripal
BRPI0914069A2 (pt) composição de vacina para uso contra o influenza
HN2011001247A (es) Inhibidores de cinana akt y p70 s6
MX2011011109A (es) Formulaciones orales de bendamustina.
EP2133092A4 (en) Oral vaccine
AR083150A1 (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
CR11078A (es) Una composicion de liberacion prolongada que comprende un derivado de somatostatina en microparticulas
BR112014000195A2 (pt) formulações de darunavir
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada
ECSP099066A (es) Vacuna combinada estreptococica
BR112012014689A2 (pt) composição de vacina
RU2013110517A (ru) Средство для профилактики или лечения неалкогольного стеатогепатита

Legal Events

Date Code Title Description
FB Suspension of granting procedure